September 14, 2011
ITCA 650 48 week Phase 2 oral presentation EASD 2011

September 14, 2011
PK/PD of ITCA 650 in Subjects with Type 2 Diabetes

September 14, 2011
Improved Patient Satisfaction with ITCA 650 vs. Exenatide Injections

June 28, 2011
ITCA 650 Phase 2 oral presentation from ADA 2011

September 22, 2010
ITCA 650 Phase 2 oral presentation EASD 2010

June 28, 2010
Comparing ITCA 650, Continuous Subcutaneous Delivery of Exenatide Via DUROS Device, vs Twice Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

November 06, 2009
Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenative at Body Temperature for 12 Months

November 06, 2009
Continuous Subcutaneous Delivery of Exenative via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes

September 30, 2009
EASD Presentation: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS Device Lowers Fasting and Postprandial Plasma Glucose

June 06, 2009
ADA 2009 Late Breaker: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS Device Lowers Fasting and Postprandial Plasma Glucose

November 18, 2008
Intarcia Therapeutics, Inc. Presents DUROS Delivery of Hepatitis C and type 2 diabetes therapies at AAPS conference

May 01, 2008
DUROS® Technology Delivers Pepties and Proteins at Consistent Rate Continuously for 3 to 12 Months